Discover the Future of Luxury: The Kayon Villas Tirta Gangga - An Opulent Eco Sanctuary, Opening Q2 2026

BALI, Indonesia, Sept. 3, 2024 /PRNewswire/ -- The Kayon Hotels & Resorts proudly announces the expansion of its esteemed portfolio with the upcoming launch of The Kayon Villas Tirta Gangga. Situated in the picturesque Ababi village in Karangasem, this eco-friendly resort is set to redefine luxury hospitality in Bali, scheduled for opening in Q2 2026. On Thursday, 29 August 2024, at 3 PM, The Kayon Hotels & Resorts celebrated a significant milestone with the groundbreaking ceremony for The Kayon Villas Tirta Gangga, marking the official commencement of this visionary project.

Spanning 1.1 hectares of lush landscapes, The Kayon Villas Tirta Gangga will feature 22 exquisite bamboo villas, each meticulously designed with sustainability and wellness in mind. Embracing the region's rich cultural heritage, the resort offers a perfect blend of traditional Balinese charm, modern eco-luxury comforts, and cutting-edge technology that elevates the guest experience to new heights.

The bamboo villas are crafted to integrate seamlessly with the diverse natural elements of the resort's setting. Rising gracefully amid cascading valleys and rice fields, these striking structures are designed to enhance and reflect their environment. Their presence among the surrounding mountains and lush terrain creates a harmonious balance that captivates all who visit, leaving a lasting impression with their elegant yet bold design. This interdisciplinary design integrates reverence for ancient traditions with a profound appreciation for nature and millennia-old cultural heritage.

"We are thrilled to introduce The Kayon Villas Tirta Gangga as the latest addition to The Kayon Hotels & Resorts family," said I Wayan Sucitra, General Manager & CEO of The Kayon Hotels & Resorts. "With its sustainable design, serene ambiance, and unparalleled hospitality, we aim to create an unforgettable experience for guests seeking healing excursions, romantic getaways, and intimate weddings."

Overlooking a magical and mesmerizing valley with breathtaking views of the serene surroundings, the resort offers vistas of Mount Lempuyang and Mount Agung as a stunning backdrop, with the infinite South Sea extending towards the horizon. The ambient air is refreshingly cool and gently breezy, providing an environment of utmost comfort and tranquility. Inspired by the natural beauty of its surroundings, The Kayon Villas Tirta Gangga offers an array of luxurious amenities, including the renowned Kepitu Restaurant, the rejuvenating Serayu Wellness & Spa, and the enchanting Puspaka Chapel.

The Kayon Villas Tirta Gangga will provide exceptional services that blend advanced technology with the warmth of Balinese hospitality. Guests will enjoy a personally curated experience, with attentive service that adds a unique touch to their stay. From bespoke wellness programs to refined dining options, every detail is designed to reflect the resort's commitment to comfort and excellence.

Once you step into the Serayu Wellness, you will be transported into a lavish water palace and feel treated like royalty. The grand design of Serayu Wellness draws inspiration from Bali's most iconic water palaces, Tirta Gangga Water Palace and Taman Ujung Water Palace, located nearby. These water palaces hold profound cosmological significance as the convergence points of the mountains and the sea: Mount Lempuyangan to the northeast, Mount Agung to the west, the Indian Ocean to the south, and the Lombok Strait to the east. This concept, known as Mandalagiri, represents the harmonious balance between earth and water, embodying tranquility and equilibrium, which is elegantly mirrored in the design and ambiance of The Kayon Villas Tirta Gangga. The spa will offer culturally-inspired treatments and therapeutic experiences that embody the tagline of Karangasem, "The Spirit of East Bali."

Guests can also enjoy breathtaking views of the tranquil rice fields that envelop the resort, providing the perfect backdrop for relaxation and rejuvenation. Additionally, the resort will feature a spectacular two-layer hanging pool, providing an exceptional vantage point of the surrounding landscape, inspired by its iconic sister establishment, The Kayon Jungle Resort.

The village is also surrounded by other historical landmarks such as the ancient Lempuyang Temple or Pura Lempuyang. Nearby, visitors can also enjoy the pristine beaches of Amed and Virgin Beach, perfect for relaxation and exploration.

Rooted in local folklore and spiritual history, Ababi village in Karangasem holds a special significance for the Balinese people. According to legend, this serene village was once home to the revered sage Empu Kuturan, whose teachings continue to inspire spiritual seekers today.

Immersed in profound spiritual heritage, surrounded by breathtaking landmarks, and nestled near stunning beaches, The Kayon Villas Tirta Gangga emerges as the ultimate destination in eastern Bali. Here, guests will discover an unrivaled fusion of ultra-luxury, eco-consciousness, cultural immersion, and natural splendor. It stands as the ultimate sanctuary for those yearning for healing and rejuvenation.

For further information or media inquiries, please contact:

The Kayon Hotels & Resorts
Email: investor@thekayonhotels.com
Phone: +6281246645312
Banjar Kepitu, Kenderan, Kec. Tegallalang, Kabupaten Gianyar, Bali 80561

About The Kayon Hotels & Resorts

The Kayon Hotels & Resorts is a distinguished hospitality group dedicated to providing unparalleled luxury experiences in Bali's most breathtaking locations. Committed to sustainability, wellness, and cultural authenticity, each property within The Kayon Hotels & Resorts portfolio offers a unique blend of Balinese charm and modern sophistication.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Discover the Future of Luxury: The Kayon Villas Tirta Gangga - An Opulent Eco Sanctuary, Opening Q2 2026

Discover the Future of Luxury: The Kayon Villas Tirta Gangga - An Opulent Eco Sanctuary, Opening Q2 2026

SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024).

This Phase I, open-label, dose-escalation and expansion study was conducted in China to assess the safety and efficacy of MVR-T3011 administered intravesically in patients with high-risk BCG-failure NMIBC. The study enrolled a broader patient population, including those with high-grade Ta, T1, or CIS +/- Ta/T1 bladder cancer, regardless of the presence of CIS. This inclusive approach aims to target a wider range of patients, potentially accelerating future trial enrollment and expanding market opportunities. The treatment was delivered via intravesical instillation at three dose levels, with weekly induction course lasting 12 weeks, followed by bi-weekly maintenance course for up to one year.

According to poster presented (cut-off as of June 27, 2024), among 14 evaluable patients, the overall 3-month complete response (CR) rate across all dose levels was 71.4% (10/14). At the 2×10⁹ PFU dose level (expected RP2D), the CR rate reached an impressive 87.5% (7/8). The study showed a favorable safety profile, with no dose-limiting toxicities (DLTs) reported and no maximum tolerated dose (MTD) reached. Additionally, MVR-T3011 treatment simplifies clinical procedure by eliminating the need for bladder prewash by nature, further reducing patient discomfort. The instillation process is both quick and efficient.

By September 15, 2024, the most recent data shows that 20 subjects have received MVR-T3011 treatment. At the RP2D dose level, the 3-month CR rate remained strong at 81.8% (9/11). Of the 9 patients who have reached the 6-month assessment, 8 have maintained CR, while 4 patients have reached the 9-month assessment and all remained in CR. We are continuing to gather additional data to support further analysis.

"There is a significant unmet need for innovative treatments for bladder cancer," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "We are highly encouraged by the preliminary safety and efficacy data from this Phase I study, especially the 3-month CR rate over 80%, along with durable responses at 6- and 9-month time points. With this early success, we are committed to accelerating clinical development of intravesical MVR-T3011 treatments for BCG-failure NMIBC patients and exploring its potential across other bladder cancer indications. Our goal is to provide a novel, effective, and well-tolerated treatment solution for patients."

About MVR-T3011

MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetic engineered oHSV with advanced backbone design aiming to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells, supporting intratumoral, intravenous and intravesical administrations. Additionally, MVR-T3011 incorporated two latest and well-validated exogenous genes, PD-1 antibody and IL-12, to further enhance immune responses in the tumor microenvironment.

About ImmVira

ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS^® (Open Vector+ Potent, Enabling, Novel & Safe) platform with solid science, technology and CMC know-how, and three derivative subplatforms including Oncolytic Virus, Cancer Vaccine and Biosynthetic Exosome, to support ongoing R&D, clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients